Lifesci Capital Has Bearish Outlook for MLYS FY2024 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Investment analysts at Lifesci Capital lowered their FY2024 earnings per share (EPS) estimates for shares of Mineralys Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($3.87) for the year, down from their previous estimate of ($3.28). The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($3.08) per share. Lifesci Capital also issued estimates for Mineralys Therapeutics’ Q4 2024 earnings at ($1.17) EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Monday, November 11th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30). During the same period last year, the business posted ($0.57) earnings per share.

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research note on Tuesday.

Mineralys Therapeutics Price Performance

Shares of MLYS opened at $12.45 on Thursday. Mineralys Therapeutics has a 12 month low of $5.85 and a 12 month high of $16.91. The stock has a fifty day moving average price of $12.98 and a 200 day moving average price of $12.65. The company has a market cap of $619.10 million, a P/E ratio of -3.81 and a beta of 1.71.

Insider Activity

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the sale, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at $3,214,108.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Mineralys Therapeutics news, insider David Malcom Rodman sold 25,482 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total value of $382,994.46. Following the completion of the sale, the insider now owns 135,974 shares in the company, valued at approximately $2,043,689.22. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.57, for a total transaction of $145,972.49. Following the completion of the sale, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,510 shares of company stock valued at $735,431. 33.24% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MLYS. Vanguard Group Inc. lifted its position in Mineralys Therapeutics by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock worth $12,690,000 after buying an additional 4,952 shares in the last quarter. Driehaus Capital Management LLC boosted its position in Mineralys Therapeutics by 40.4% during the 2nd quarter. Driehaus Capital Management LLC now owns 257,371 shares of the company’s stock worth $3,011,000 after buying an additional 74,074 shares during the period. Nantahala Capital Management LLC boosted its position in Mineralys Therapeutics by 60.1% during the second quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company’s stock valued at $6,230,000 after acquiring an additional 200,000 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Mineralys Therapeutics in the 2nd quarter valued at $145,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Mineralys Therapeutics by 72.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 84,762 shares of the company’s stock valued at $992,000 after buying an additional 35,634 shares during the period. 84.46% of the stock is currently owned by institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.